The Clinical Practice Guidelines Jointly Developed by the Pharmacy and Pediatrics Departments of Peking University Third Hospital Win the 2022 China STAR Clinical Pharmacy Specialty's Best Guideline/Consensus Award

Author: Zhou Pengxiang

Link Address：https://www.puh3.net.cn/info/1971/113811.htm

The comprehensive rating results of the 2022 China Guideline/Consensus Scientific, Transparent, and Applicable Rating Tool (STAR) were announced. The "Clinical Practice Guidelines for the Rational Use of 
Oral H1 Antihistamines in Children (2022 Edition)," jointly developed by the Allergy Branch of the Chinese Medical Association, the Pediatric Committee of the China Association of Medical Education, 
the Pharmaceutical Management Committee of the Chinese Maternal and Child Health Association, and the Pediatric Allergy, Immunology, and Rheumatology Branch of the Asia Pacific Society of Immunology, 
with the Drug Evaluation Center of the Medical Department of Peking University as the methodological unit, and led by the Pediatrics and Pharmacy Departments of Peking University Third Hospital with the 
collaboration of over 40 national experts, was awarded the 2022 China STAR Clinical Pharmacy Specialty's Best Guideline/Consensus Award.

The guideline focuses on the most commonly used oral antihistamines in children. It was developed based on scientifically standardized clinical practice guideline formulation methods and processes, integrating the best current evidence-based medicine, multi-disciplinary expert experience, and patient family preferences, using the GRADE evidence rating method and formal consensus processes. It resulted in 19 recommendation points across 8 aspects, covering the treatment role of oral H1 antihistamines in children with allergic diseases, age range, dosage, course of treatment, adjustments for liver and kidney dysfunction, interactions, adverse reactions, and compliance. These guidelines provide standardization and guidance for the rational use of such medications in children. This work was supported by the National Major Scientific and Technological Special Project and the National Natural Science Foundation of China.